News

Under the terms of the agreement, Sangamo is expected to provide a worldwide, fully paid, perpetual, royalty free, non-exclusive, license for the use of certain ZFP Nuclease (ZFN) reagents for

ATL-962, which was discovered and created by Alizyme, is expected to be an agent to treat obesity and related diabetes or dyslipidemia through its mechanism of action which

According to the company, Tongbianling capsule is a generic traditional Chinese medicine and highly effective in treating one-time abdominal distention constipation, bedridden constipation and elderly chronic constipation. Tongbianling

In Northwest Biotherapeutics’s (NWBT) trial, the two patients who have received treatment attained eight months and six months without progression, respectively. Each of these NWBT patients had metastases

TPI 1100 is a inhaled inhibitor against phosphodiesterases (PDEs), PDE 4 and PDE 7. PDEs are a group of enzymes that are validated targets for chronic obstructive pulmonary

AstraZeneca is evaluating the contents of the complete response letter (CRL) and the proposed labeling revisions. AstraZeneca will continue discussions with the FDA and will provide a response

The drug candidate is currently in a Phase I/II clinical trial for the treatment of recurrent malignant melanoma. The company had previously received orphan designation for 131I-TM601 in

The relationship between the Hubbard and Harrington health systems has the potential to collaborate in ventures designed in the best interest of their patients, said Harrington Hospital. Chris

Final approval of this product is expected upon resolution of patent litigation. According to Teva, the brand product had annual sales of approximately $3.8 billion in the US